Cigna slides as investors digest CEO succession news and post–ex-dividend pressure

The Cigna Group (CI) is down 4.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued selling after Cigna disclosed a planned CEO transition, which can create short-term uncertainty even when fundamentals are unchanged. The decline may also be amplified by a mechanical post–ex-dividend adjustment following this week’s dividend cutoff.

Details:

Cigna announced that CEO David M. Cordani plans to retire on July 1, 2026, with President and COO Brian Evanko named as the next CEO, and Cordani expected to become executive chair.

Alongside the leadership update, the company reaffirmed its full-year 2026 adjusted income from operations outlook (at least $30.25 per share), which may have shifted the market’s focus to governance/transition risk rather than guidance upside.

The stock went ex-dividend on March 5, 2026, for a $1.56 quarterly cash dividend payable March 19, 2026; stocks often trade lower by roughly the dividend amount after the ex-date.

This move could also reflect broader, sentiment-driven selling in managed-care names as traders reassess near-term positioning after recent announcements.

Sources:

The Cigna Group (Newsroom), Nasdaq, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CI Insider Trading Activity

$CI insiders have traded $CI stock on the open market 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $CI stock by insiders over the last 6 months:

BRIAN C EVANKO (See Remarks) sold 5,368 shares for an estimated $1,610,400
DAVID CORDANI (Chairman & CEO) purchased 4,134 shares for an estimated $999,916
NICOLE S JONES (See Remarks) sold 2,307 shares for an estimated $666,515
EVERETT NEVILLE (See Remarks) sold 1,719 shares for an estimated $496,636

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$CI Hedge Fund Activity

We have seen 687 institutional investors add shares of $CI stock to their portfolio, and 948 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 6,882,711 shares (-74.7%) from their portfolio in Q4 2025, for an estimated $1,894,328,548
PRICE T ROWE ASSOCIATES INC /MD/ removed 5,032,153 shares (-44.5%) from their portfolio in Q4 2025, for an estimated $1,384,999,470
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 3,738,636 shares (-99.9%) from their portfolio in Q4 2025, for an estimated $1,028,984,786
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 3,141,844 shares (+13333.2%) to their portfolio in Q4 2025, for an estimated $864,729,724
DODGE & COX added 1,833,389 shares (+19.7%) to their portfolio in Q4 2025, for an estimated $504,603,654
CAPITAL RESEARCH GLOBAL INVESTORS removed 1,245,656 shares (-39.2%) from their portfolio in Q4 2025, for an estimated $342,841,900
BOSTON PARTNERS added 1,243,056 shares (+314.6%) to their portfolio in Q4 2025, for an estimated $342,126,302

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CI Government Contracts

We have seen $381,651 of award payments to $CI over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

THE CONTRACTOR SHALL PROVIDE MEDICAL, VISION AND DENTAL INSURANCE AS DESCRIBED WITHIN THE PERFORMANCE WORK ...: $381,651

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$CI Congressional Stock Trading

Members of Congress have traded $CI stock 6 times in the past 6 months. Of those trades, 1 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $CI stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 12/19 and 1 sale worth up to $15,000 on 11/12.
REPRESENTATIVE JULIE JOHNSON has traded it 3 times. They made 0 purchases and 3 sales worth up to $45,000 on 12/18, 11/13, 09/25.
REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$CI Analyst Ratings

Wall Street analysts have issued reports on $CI in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 02/02/2026
Truist Securities issued a "Buy" rating on 01/05/2026
Goldman Sachs issued a "Buy" rating on 11/04/2025
TD Cowen issued a "Buy" rating on 11/04/2025

To track analyst ratings and price targets for $CI, check out Quiver Quantitative's $CI forecast page.

$CI Price Targets

Multiple analysts have issued price targets for $CI recently. We have seen 10 analysts offer price targets for $CI in the last 6 months, with a median target of $333.5.

Here are some recent targets:

Jessica Tassan from Piper Sandler set a target price of $370.0 on 03/03/2026
David Macdonald from Truist Securities set a target price of $350.0 on 02/17/2026
Charles Rhyee from TD Cowen set a target price of $338.0 on 02/09/2026
Andrew Mok from Barclays set a target price of $303.0 on 02/06/2026
Jason Cassorla from Guggenheim set a target price of $334.0 on 02/06/2026
Ben Hendrix from RBC Capital set a target price of $333.0 on 02/06/2026
Lance Wilkes from Bernstein set a target price of $294.0 on 11/12/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.